Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 8/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RARA | P10276 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6878639 | 1.00 | RARB (0.44) | RARBTP53TSHRALDH1A1PLA2G4B | |
| SCHEMBL6876258 | 0.82 | ESR1 (0.47) | TSHRALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL9555292 | 0.81 | ABCG2 (0.38) | TSHRALDH1A1MAPT | |
| SCHEMBL702726 | 0.80 | EGFR (0.41) | TP53MAPTTDP1L3MBTL1 | |
| SCHEMBL702727 | 0.80 | EGFR (0.41) | TP53MAPTTDP1L3MBTL1 | |
| SCHEMBL6965007 | 0.80 | EGFR (0.41) | TP53MAPTTDP1L3MBTL1 | |
| SCHEMBL17783836 | 0.77 | ALDH1A1 (0.39) | TSHRALDH1A1 | |
| SCHEMBL1661860 | 0.77 | NFE2L2 (0.42) | — | |
| SCHEMBL3175226 | 0.76 | CTDSP1 (0.33) | ALDH1A1MAPT | |
| SCHEMBL3175215 | 0.76 | CTDSP1 (0.33) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825233-B2 | SUBSTITUTED BONZOIC ACID DERIVATIVES, USEFUL FOR PREVENTING AND/OR TREATING TUMORS, ARTHRITIS, AND NON-MALIGNANT SKIN DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-30 | — | — | US | disclosed |
| US-20020193421-A1 | Compounds having retinoid-like activity | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-19 | — | — | US | disclosed |
| WO-2002065984-A2 | COMPOUNDS HAVING RETINOID-LIKE ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193421-A1 | Compounds having retinoid-like activity | RARA, RARG, RARB | RARB 3/4885TP53 194/4885TSHR 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.